Alkaptonuria (AKU)
A rare inherited disorder of tyrosine metabolism, often first noticed as darkening urine, that leads over decades to pigment deposition in cartilage and connective tissue (ochronosis) and progressive joint disease.
- Joint health monitoring
- Dietary guidance support
- Genetic counseling
- Estimated Prevalence
- ~1 in 250,000–1,000,000
- Typical Onset of Joint Disease
- Adulthood (30s onward)
- Primary Gene
- HGD
- Approved Therapy
- Nitisinone
Condition Overview
Alkaptonuria (AKU) is a rare inherited disorder of tyrosine metabolism caused by deficiency of homogentisate 1,2-dioxygenase (HGD). This deficiency leads to accumulation of homogentisic acid, which is excreted in large amounts in the urine and slowly deposits as a dark pigment in cartilage and connective tissue, a process called ochronosis.
While darkening of urine on standing is often the first noticeable sign, sometimes from infancy, the more significant long-term impact is progressive joint and spine disease that typically becomes apparent in adulthood. Early recognition allows monitoring of joint health and consideration of nitisinone therapy, which reduces homogentisic acid production.
Types and Subtypes
AKU is a single biochemical entity, but its clinical course is often described by the body systems affected as pigment deposition progresses.
Symptoms and Signs
Symptoms evolve over decades, starting with a biochemical curiosity and progressing to significant musculoskeletal disease.
Causes and Risk Factors
AKU is caused by inherited biallelic mutations in the HGD gene, with disease severity influenced mainly by cumulative pigment exposure over time rather than external lifestyle factors.
Diagnosis and Investigations
Diagnosis is often suspected from characteristic urine darkening or incidental ochronotic findings, and confirmed biochemically and genetically.
Disease Severity and Risk Stratification
AKU progression is generally described by age-related accumulation of pigment and resulting organ involvement rather than a formal staging system.
Standard Treatment Options
Management combines disease-modifying therapy where appropriate with proactive monitoring and treatment of joint and organ complications.
Advanced & Emerging Therapies
Nitisinone represents the main targeted therapy for AKU, with surgical options available for advanced joint disease.
Enzyme Pathway Inhibitor
Nitisinone
Inhibits 4-hydroxyphenylpyruvate dioxygenase, reducing homogentisic acid production; approved for AKU based on evidence of slowed disease progression.
Orthopedic Intervention
Joint replacement surgery
Hip, knee, or shoulder replacement for advanced ochronotic arthropathy significantly affecting mobility.
Cardiac Intervention
Heart valve repair or replacement
Considered when ochronotic pigment deposition causes significant valvular dysfunction.
Biomarkers & Precision Medicine
Biomarker monitoring in AKU tracks both the underlying metabolic abnormality and downstream organ involvement.
When a Second Opinion May Be Important
Because AKU is rare and slowly progressive, periodic specialist review helps ensure monitoring keeps pace with disease evolution.
Clinical Trials and Research
Prognosis and Key Outcome Factors
AKU does not shorten life expectancy on its own, but untreated disease can lead to substantial joint disability and, in some patients, cardiac or renal complications over decades.
Supportive Care and Living With AKU
Supportive care in AKU focuses on preserving joint function and quality of life across a long disease course.
How CancerFax Helps You Explore Treatment Options
CancerFax helps patients with Alkaptonuria coordinate specialist review of metabolic and joint imaging results and connect with centers experienced in nitisinone therapy and ochronotic arthropathy management.
Get a free case reviewFrequently Asked Questions
It is a rare inherited disorder of tyrosine metabolism that causes urine to darken and, over decades, leads to pigment deposition in cartilage and joints.
It is caused by mutations in the HGD gene that lead to deficiency of an enzyme needed to fully break down tyrosine, causing homogentisic acid to build up.
Homogentisic acid in the urine oxidizes and darkens on standing or exposure to air, which is often the first noticeable sign of AKU.
Yes, over time pigment deposition in cartilage (ochronosis) leads to progressive joint and spine disease, usually becoming apparent in adulthood.
Nitisinone is an approved therapy that reduces homogentisic acid production and has been shown to slow disease progression.
Yes, it is inherited in an autosomal recessive pattern, meaning both parents must carry a mutated HGD gene copy.
Pigment deposition can affect heart valves over time, so periodic cardiac monitoring is part of comprehensive care.
Diagnosis is confirmed by markedly elevated homogentisic acid in the urine, supported by genetic testing of the HGD gene.
Yes, the biochemical abnormality and dark urine can be present from infancy, even though joint disease typically develops later in adulthood.
Yes. CancerFax can help you organize metabolic and imaging results for specialist review, coordinate a second opinion, and connect you with centers experienced in nitisinone therapy and joint disease management for AKU.
Considering a Specialist Review for AKU?
Send your metabolic and joint imaging results so a specialist can help refine your management plan.